Sonographic 3D Measurement of Fetal Thymus May be Used to Predict the Small Baby in Pregnancy.
NCT ID: NCT05328453
Last Updated: 2022-04-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2016-03-01
2017-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Investigators performed a prospective clinical study in 100 pregnant women in their second trimester of pregnancy who attended the Fetal Medicine Unit of the Medicine Faculty of Karadeniz Technical University during the study period. Maternal age, gravida, para, BMI, blood pressure, gestational age, BPD, FL ,AC, EFW and fetal timus volume measured with VOCAL programme are recorded. For all patients routine clinical and ultrasound examinations were performed during pregnancy. Gestational age at birth, way of birth and newborn birthweight were recorded. The results were statistically compared in the SPSS 13.0 program. Student-t test and chi-square test were used for statistical analysis. ROC curve analysis was used for limit values. The data of patients with IUGR and without IUGR were compared. The ability of the thymus volume to predict the IUGR was tested using binary logistic regression analysis. P value \<0.05 was considered statistically significant.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Fetal Thymus Volumes of Pregnant Women With In Vitro Fertilization (IVF) and Spontaneous Pregnant Women.
NCT05347433
Follicular Fluid Sialic Acid Levels in IVF Cycles
NCT03745027
Risk of Pulmonary and Venous Thromboembolism in Pregnancies After in Vitro Fertilization
NCT01524393
Assesment of Embryo Viability and Re-expansion After Thawing in Blastocyst Stage Embryos
NCT05474833
Evaluation of Blastocyst Morphology and Quality in Patients With Embryo Transfer at the Blastocyst Stage
NCT05510557
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
3D Fetal thymus volume (TV) was measured by using a VOLUSON E-10 ultrasonography device, by a single researcher experienced in the use of obstetric ultrasound with a transabdominal volumetric probe. The fetal thymus, transverse section of the fetal chest, and the 3 vessel sections were visualised, then the 3D US modality was activated and the thymus volume was obtained immediately with the same probe.
All cases were followed up in terms of pregnancy complications (IUGR development) until delivery.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pregnant women at 15-24 gestation.
Routine fetal ultrasonography at 15-24 weeks. All sonographic measurements including 3D fetal thymus calculation was measured.
Fetal prenatal ultrasonographic evaluation.
Routine fetal ultrasonography at 15-24 weeks. All sonographic measurements including 3D fetal thymus calculation was measured.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fetal prenatal ultrasonographic evaluation.
Routine fetal ultrasonography at 15-24 weeks. All sonographic measurements including 3D fetal thymus calculation was measured.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Who presented at the polyclinic for routine antenatal follow-up at 15-24 weeks
* Had no complaints.
* Had normal renal, hepatic, and thyroid functions test results.
Exclusion Criteria
* systemic disease,
* collagen disorder,
* hypercholesterolemia,
* hemoglobinopathy
* history of neoplasm,
* current or previous cardiovascular disease,
* the use of any drugs within the 3 months before the pregnancy,
* multiple pregnancy,
* current smoking,
* abnormal renal, hepatic, or thyroid function test results,
* the presence of any findings of fetal chromasomal or structural anomaly,
* refusal to participate in the study.
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Karadeniz Technical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Suleyman Guven
Prof. Dr.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Suleyman Guven, Prof
Role: STUDY_CHAIR
Karadeniz Technical University Faculty of Medicine Department of Obs and Gyn
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016/181
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.